Literature DB >> 11352906

Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface.

H Zhang 1, S Lu, S L Morrison, S Tomlinson.   

Abstract

Recombinant soluble complement inhibitors hold promise for the treatment of inflammatory disease and disease states associated with transplantation. Targeting complement inhibitors to the site of complement activation and disease may enhance their efficacy and safety. Data presented show that targeting of decay-accelerating factor (DAF, an inhibitor of complement activation) to a cell surface by means of antibody fragments is feasible and that cell-targeted DAF provides significantly enhanced protection from complement deposition and lysis compared with soluble untargeted DAF. An extracellular region of DAF was joined to an antibody combining site with specificity for the hapten dansyl, at the end of either C(H)1 or C(H)3 Ig regions. The recombinant IgG-DAF chimeric proteins retained antigen specificity and bound to dansylated Chinese hamster ovary cells. Both soluble C(H)1-DAF and C(H)3-DAF were effective at inhibiting complement-mediated lysis of untargeted Chinese hamster ovary cells at molar concentrations within the range reported by others for soluble DAF. However, when targeted to a dansyl-labeled cell membrane, C(H)1-DAF was significantly more potent at inhibiting complement deposition and complement-mediated lysis. Cell-bound C(H)1-DAF also provided cells with protection from complement lysis after removal of unbound C(H)1-DAF. Of further importance, the insertion of a nonfunctional protein domain of DAF (the N-terminal short consensus repeat) between C(H)1 and the functional DAF domain increased activity of the fusion protein. In contrast to C(H)1-DAF, C(H)3-DAF was not significantly better at protecting targeted versus untargeted cells from complement, indicating that a small targeting vehicle is preferable to a large one. We have previously shown that for effective functioning of soluble complement inhibitor CD59, binding of CD59 to the cell surface close to the site of complement activation is required. Significantly, such a constraint did not apply for effective DAF function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352906     DOI: 10.1074/jbc.M100436200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.

Authors:  Chen Song; Zhikai Xu; Jianting Miao; Jiang Xu; Xingan Wu; Fanglin Zhang; Hong Lin; Zhuyi Li; Henry J Kaminski
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

2.  Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic.

Authors:  Deborah A Fraser; Claire L Harris; Richard A G Smith; B Paul Morgan
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

3.  Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.

Authors:  C L Harris; A S Williams; S M Linton; B P Morgan
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

4.  Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.

Authors:  Hongbin Song; Chun He; Christian Knaak; Joel M Guthridge; V Michael Holers; Stephen Tomlinson
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 5.  Tissue-targeted complement therapeutics.

Authors:  Stephen Tomlinson; Joshua M Thurman
Journal:  Mol Immunol       Date:  2018-07-07       Impact factor: 4.407

6.  Lupus nephritis: an overview of recent findings.

Authors:  Alberto de Zubiria Salgado; Catalina Herrera-Diaz
Journal:  Autoimmune Dis       Date:  2012-03-22

7.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12

8.  Targeting therapy to the neuromuscular junction: proof of concept.

Authors:  Linda L Kusner; Namita Satija; Georgiana Cheng; Henry J Kaminski
Journal:  Muscle Nerve       Date:  2014-05       Impact factor: 3.217

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.